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Sevelamer hydrochloride prevents ectopic calcification and re-
nal osteodystrophy in chronic renal failure rats.
Background. Hyperphosphatemia is associated with severe
complications, including ectopic calcification of soft tissues, sec-
ondary hyperparathyroidism, and renal osteodystrophy (ROD).
Sevelamer hydrochloride is a nonabsorbed calcium- and metal-
free phosphate binder that lowers serum phosphorus levels
in hemodialysis patients. This study examined the efficacy of
sevelamer in preventing ectopic calcification of soft tissues and
ROD in adenine-induced renal failure rats.
Methods. Male, 12-week-old Wistar-Jcl rats were freely fed
an adenine diet (0.75 g adenine in 100 g normal diet) for four
weeks. After three weeks of the adenine diet, when serum
phosphorus levels had significantly increased, the rats were
freely fed a normal diet that contained 1% or 2% of sevelamer
for another five weeks. Time course changes of serum levels
of phosphorus, calcium, and parathyroid hormone (PTH) were
measured. At the end of the study, calcium and phosphorus
levels in the heart and aorta were measured, and the calcifica-
tion of kidney, heart, aorta, and stomach were histopathologi-
cally examined. The severity of ROD was evaluated by a histo-
pathologic and morphometric analysis of the femurs.
Results. Compared with the adenine controls (N  10), the
sevelamer-treated (1%, N  6; and 2%, N  10) groups of
adenine-induced renal failure rats had reduced serum phospho-
rus, serum calcium  phosphorus product, and serum PTH
levels. Moreover, in the treatment groups, sevelamer sup-
pressed calcification of the aorta media, and also the osteoid
volume, fibrosis volume, and porosity ratio of femurs.
Conclusion. These results suggest that sevelamer treatment
might contribute to the suppression of ectopic calcification and
ROD.
In chronic renal failure and dialysis patients, hyper-
phosphatemia is caused by an accumulation of phosphate
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resulting from the impaired urinary excretion of phos-
phate [1, 2]. Dialysis and restriction of dietary phosphate
are insufficient to prevent hyperphosphatemia in patients
with renal insufficiency [3]. Hyperphosphatemia is asso-
ciated with severe complications, including ectopic calci-
fication of soft tissues, secondary hyperparathyroidism,
and renal osteodystrophy (ROD) [2]. Hyperphosphate-
mia is accompanied by elevated levels of serum cal-
cium phosphorus product. Most studies on myocardial,
vascular, and coronary artery calcification among end-
stage renal disease (ESRD) patients have reported a strong
association between calcification and serum phosphorus
and/or calcium phosphorus product levels [4]. Further-
more, secondary hyperparathyroidism induces high turn-
over bone disease (ROD), which is characterized by an
increased activation of osteoblasts and osteoclasts with
corresponding elevated rates of bone formation [5–7].
Sevelamer hydrochloride (Renagel) is a nonabsorbed
calcium- and metal-free phosphate binder that lowers
the serum phosphorus levels in hemodialysis patients
[8–10]. Sevelamer is a hydrogel of crosslinked poly [ally-
lamine hydrochloride], which is completely resistant to
digestive degradation and is not absorbed from the gas-
trointestinal tract. Many benefits have been clinically
reported as to the efficacy of lowering the serum phos-
phorus, calcium  phosphorus product and parathyroid
hormone (PTH) levels with minimal effects on serum
calcium [8-11]. Recently, it has also been reported that
sevelamer plays a role in decreasing the progression of
coronary and aortic calcification in hemodialysis pa-
tients, possibly by reducing the serum calcium  phos-
phorus product or serum low-density lipoprotein choles-
terol levels [12].
In this study, we examined the effectiveness of seve-
lamer in preventing the ectopic calcification of soft tis-
sues and ROD in adenine-induced renal failure rats. Our
data showed that administration of an adenine diet to
rats, resulting in the deposition of 2,8-dihydroxyadenine
in the renal tubules, induced severe chronic renal failure
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Fig. 1. The experimental design. From day 21 to day 7, adenine diet
was administered for the three groups (adenine-administered group,
1% or 2% sevelamer-administered group). At day 7, adenine diet was
stopped and after that normal diet was used. At day 0, the administration
of sevelamer was started and sevelamer was administered at 1% or 2%
mixtured diet for 5 weeks.
due to the degeneration of the proximal and distal tu-
bules and interstitial fibrosis [13, 14]. It is also known
that this animal model results in hyperphosphatemia re-
lated to severe, chronic renal failure [14–16]. This current
study demonstrated an increase in ectopic calcification
of soft tissues, including the blood vessels, kidney, and
muscular layer of the stomach, as well as elevated levels
of serum calcium  phosphorus product in adenine-
induced renal failure rats. Furthermore, characteristics ob-
served when ROD was induced by hyperparathyroidism
in the adenine-induced renal failure rats included osteitis
fibrosa, bone resorption cavities, and increased osteoid.
The results of this study, with regard to ectopic calcifica-
tion, are consistent with the effect on sevelamer in a
previously published clinical study, and furthermore,
these data suggest sevelamer’s potential to prevent the
high turnover type of ROD in ESRD patients.
METHODS
Materials
Sevelamer hydrochloride (Renagel), a crosslinked
poly (allylamine hydrochloride), was synthesized by the
Dow Chemical Company (Midland, MI, USA) and sup-
plied by Chugai Pharmaceutical Co., Ltd. (Tokyo, Ja-
pan). Cellulose was obtained from Sigma Chemical Co.
(St. Louis, MO, USA).
Experimental animals
Twelve-week-old male Wistar rats were purchased
from Clea Japan, Inc., (Tokyo, Japan). Rats were main-
tained in sterilized cages and fed standard powder rodent
chow containing 1.06% calcium and 1.03% phosphate
(CE-2; Clea Japan, Inc.).
Study design
After an acclimatization period of six days, rats were
fed a CE-2 diet containing 0.75% adenine, 1.06% cal-
cium, and 0.92% phosphate (adenine diet; Clea Japan,
Inc.). The study design is shown in Figure 1. Five rats
(the normal-control group) were fed a normal CE-2 diet.
After three weeks of the adenine-diet feeding, when
serum phosphorus levels significantly increased, the ade-
nine-induced renal failure rats were randomly divided
into three experimental groups that were matched with
respect to serum phosphorus and creatinine levels: an
adenine-control group; a 1% sevelamer-treated group;
and a 2% sevelamer-treated group. In order to control
the concentrations of sevelamer, it was mixed into a
powdered adenine diet or a powdered CE-2 diet. In
order to maintain a constant phosphorus concentration
in the diet, the diets for the normal-control group and
adenine-control group were blended with 2% cellulose,
whereas the diet for the 1% sevelamer-treated group
was blended with 1% cellulose. The rats were freely fed
the adenine diet containing the sevelamer (1% or 2%)
for seven days. Then, the adenine diet was changed and
the rats were freely fed a normal diet that contained the
sevelamer at either 1% or 2% for the next 28 days. Blood
samples were collected to analyze the serum parameters
on days 7, 21, and 35.
The animals used in this experiment were treated in
accordance with Chugai Pharmaceutical’s ethical guide-
lines of animal care, handling, and termination.
Blood biochemistry
Serum phosphorus, calcium, and creatinine levels were
determined with an autoanalyzer (7170-E, Hitachi, Tokyo,
Japan). Serum PTH concentrations were determined by
using a two-site immunoradiometric assay (IRMA) with
the rat PTH IRMA kit (Immutopics, Inc., San Clemente,
CA, USA).
Calcium and phosphorus contents in thoracic aorta
At the end of the study, the thoracic aortas were re-
moved and frozen at20C until analysis. After lyophili-
zation, using a freeze drier (FD-5N; Tokyo Rikakikai
Co., Ltd., Tokyo, Japan), the dried aorta was defatted
with chloroform and methanol (2:1) for 48 hours and
dehydrated by acetone for three hours. The dried sam-
ples were incinerated to ashes at 900C for 12 hours
using an electric muffle furnace (KDF-S90; Denken Co.,
Ltd., Kyoto, Japan), then extracted with HCl and diluted
with distilled water. The levels of calcium and phospho-
rus in the aorta were determined and represented as the
weight of calcium or phosphorus per dry weight of aorta.
Histopathology
Calcification of soft tissues. Aorta, heart, kidney, and
stomach were fixed in a 20% neutral-buffered formalin
and embedded in paraffin and sectioned by standard
methods. The sections were stained using the von Kossa
method. Aortas were examined as to the expression of
bone matrix proteins osteopontin (monoclonal antibody
for osteopontin; LSL Co., Ltd., Tokyo, Japan) and osteo-
calcin (monoclonal antibody for osteocalcin; LSL Co.,
Ltd.) by immunohistochemistry.
Renal osteodystrophy in femurs. The left femur was
fixed in a 20% neutral-buffered formalin and embedded
in paraffin after decalcification and sectioned by standard
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Fig. 2. Sevelamer lowers serum phosphorus levels in adenine-induced
renal failure rats. Data are mean  SE. #P  0.05 vs. normal control;
*P  0.05; ***P  0.001 vs. adenine control.
Fig. 3. Effect of sevelamer on serum calcium in adenine-induced renal
failure rats. Data are mean  SE. #P  0.05 vs. normal control; **P 
0.01; ***P  0.001 vs. adenine control.
methods. The sections were stained with hematoxylin
and eosin (HE).
Morphometrical analysis in ROD
The right femur was fixed in 70% ethanol and embed-
ded in methyl metacrylate without decalcification. After
Villanueva bone staining, cross-sections of the middle
femur, 20 to 30 m thick, were obtained with a cutting
and grinding system (BS-3000N, MG-4000; Exakt-Appara-
tebau, Norderstedt, Germany).
Histomorphometry was performed under fluorescent
light microscopy (OPTIPHOT-2; Nikon, Tokyo, Japan)
using a semiautomatic, image analyzer system (Bone
Histomorphometry, Version 3; System Supply Co., Ltd.,
Nagano, Japan). For each section, measurements were
performed at a magnification of 156.
Nomenclature, symbols, and units used in this study
are those defined in the Report of the American Society
for Bone and Mineral Research Nomenclature Commit-
tee [17]. Osteoid volume (OV), fibrosis volume (Fb.V),
and porosity ratio (Po.Ar/Ct.Ar) were measured as the
markers related to ROD.
Statistical analysis
Data were expressed as the mean  standard error
(SE). Statistical analysis was performed using the SAS
Fig. 4. Sevelamer lowers serum calcium phosphorus product in ade-
nine-induced renal failure rats. Data are mean  SE. #P  0.05 vs.
normal control; *P  0.05; ***P  0.001 vs. adenine control.
Fig. 5. Effect of sevelamer on serum creatinine in adenine-induced
renal failure rats. Data are mean  SE. #P  0.05 vs. normal control.
system (SAS Institute, Inc., Cary, NC, USA). An un-
paired t test was used to compare the adenine-control
group with the normal-control group. The Dunnett mul-
tiple comparisons test was used to compare the seve-
lamer-treated groups with the adenine-control group
with regard to the bone histomorphometric data, aorta
phosphorus levels, and aorta calcium levels. The Dunnett
test, adjusted by the baseline value as the covariate, was
used to compare the sevelamer-treated groups with the
adenine-control group with regard to the repeated mea-
surements. Serum PTH was analyzed as the logarithmic
value of the serum PTH concentration. For histopathol-
ogy analysis, a Wilcoxon rank-sum test was used to com-
pare the adenine-control group with the normal-control
group [8–10]; and with a nonparametric Dunnett test
(Steel test) was used to compare the sevelamer-treated
groups with the adenine-control group. Statistical sig-
nificance was defined as P  0.05, two-sided.
RESULTS
Serum phosphorus, calcium, calcium  phosphorus
product, and creatinine levels
To determine if sevelamer lowers serum phosphorus
levels, we used an experimental rat model of adenine-
induced renal failure with hyperphosphatemia. The renal
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Fig. 6. Effects of sevelamer on aorta calcium
and phosphorus contents in adenine-induced
renal failure rats. (A ) Calcium in aorta was
significantly more elevated in the adenine-
control group than in the normal-control
group. Calcium contents in aorta were signifi-
cantly decreased in both 1% and 2% seve-
lamer-treated groups, compared with the ade-
nine-control group. (B ) Phosphorus levels in
the aorta were significantly more elevated in
adenine-control group than that in the nor-
mal-control group. Phosphorus levels in the
aorta were significantly decreased in both 1%
and 2% sevelamer-treated groups compared
with the adenine-control group. Data are pre-
sented as mean  SE. #P  0.05 vs. normal-
control group; **P  0.01 vs. adenine-control
group.
Table 1. Effect of sevelamer on calcification of soft tissues
Normal (N  5) Adenine control (N 10) Adenine-1% sevelamer (N 6) Adenine-2%sevelamer(N10)
                   
Aorta media 5 0 0 0 0 1 1 0 1 7 5 0 0 1 0 9 0 0 0 1
P  0.003a P  0.006b P  0.001b
Kidney 5 0 0 0 0 3 1 3 1 2 4 1 1 0 0 7 2 1 0 0
P  0.023a P  0.134b P  0.045b
Stomach muscular layer 5 0 0 0 0 0 0 3 5 2 1 3 2 0 0 9 0 0 1 0
P  0.002a P  0.051b P  0.001b
Stomach mucosa 5 0 0 0 0 1 1 7 1 0 1 3 2 0 0 9 0 0 1 0
P  0.003a P  0.445b P  0.002b
, No change; , very slight; , slight; , moderate; , severe.
a vs. normal (Wilcoxon rank-sum test)
b vs. adenine control (Steel test)
failure rats with hyperphosphatemia, which were fed sev-
elamer, showed decreased levels of serum phosphorus
and serum calcium  phosphorus product. Administra-
tion of sevelamer was started three weeks into the ade-
nine treatment, after the serum phosphorus levels had
been significantly elevated (11.2 mg/dL). At days 7 and
21, significantly lower levels of serum phosphorus were
reported in the treatment groups receiving sevelamer,
while serum phosphorus levels in the adenine-control
group were significantly elevated during the first seven
days of sevelamer administration before returning to the
same phosphorus level as the normal-control group by
the end of the study (Fig. 2).
As for the serum calcium levels, they were lower in
the adenine-control group compared with the normal
control group, while those in the sevelamer-treated
groups were slightly elevated compared with the ade-
nine-control group throughout the study (Fig. 3).
In the adenine-control group, serum phosphorus and
calcium  phosphorus product levels were significantly
elevated at day 7 and 21 of treatment before returning
to the same level as the normal-control group by the
end of the study (Fig. 4). The product was lower at day
7 for both sevelamer 1% and 2%, and also lower at
day 21 for sevelamer 2%. As for the serum creatinine,
sevelamer did not improve the serum creatinine levels,
although there were the tendencies to decrease in all
groups after the adenine diet was stopped (Fig. 5).
Ectopic calcification
In order to examine the effectiveness of sevelamer in
preventing ectopic calcification of soft tissues, the cal-
cium and phosphorus levels of the thoracic aorta were
analyzed, and calcifications of kidney, heart, aorta, and
stomach were histopathologically examined by von
Kossa staining. In the adenine-control group, the calcium
and phosphorus levels of the thoracic aorta were signifi-
cantly elevated compared to those in the normal-control
group and in the sevelamer-treated groups, indicating
that sevelamer significantly suppressed an increase in
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Fig. 7. Effect of sevelamer on calcification of
thoracic aorta. (A to D ) von Kossa stains of
thoracic aorta of normal-control group (A),
adenine-control group (B, C), or 2% seve-
lamer-treated rat (D) at day 35 after adminis-
tration. Sevelamer prevented the calcification
of aorta media in the adenine-induced renal
failure rats. Magnification of (A, B, D), 2;
magnification of (C) 10.
Fig. 8. Expressions of osteopontin and osteocalcin were observed in calcified regions of thoracic aorta by immunohistochemistry. The aortas of
normal rats were negative for osteopontin (A ) and osteocalcin (D ). The regions of ectopic calcification in adenine-induced renal failure rats were
positive for osteopontin (B ) and osteocalcin (E ). The aortas not expressing ectopic calcification by 2% sevelamer administration were negative
for osteopontin (C ) and osteocalcin (F ). Magnification, 40.
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Fig. 9. Effect of sevelamer on serum PTH in adenine-induced renal
failure rats. Serum parathyroid hormone (PTH) was significantly ele-
vated in adenine controls compared to normal controls. Sevelamer
significantly suppressed serum PTH increases in adenine-induced renal
failure rats. Data are mean  SE. #P  0.05 vs. normal-control group;
*P  0.05; **P  0.01 vs. adenine-control group.
the calcium and phosphorus levels of the thoracic aorta
compared with the adenine-control group (Fig. 6). In
the histopathologic examination of the thoracic aorta
media (von Kossa staining), ectopic calcification was ob-
served as either moderate or severe in 8/10 animals in
the adenine-control group, while no ectopic calcifications
were observed in the normal-control group (Table 1, Fig.
7). Osteopontin and osteocalcin were expressed in the
regions with ectopic calcification (Fig. 8). In this study
sevelamer significantly suppressed the ectopic calcifica-
tion (Fig. 7) and expression of osteopontin and osteocal-
cin (Fig. 8) in the aorta media, compared with the ade-
nine-control group. In the kidney, ectopic calcification
was also histopathologically observed in the renal tu-
bules and tubular basement membrane in the adenine-
control group and not in the normal-control group (Ta-
ble 1). Sevelamer significantly prevented calcification in
the kidney. Furthermore, sevelamer significantly pre-
vented the calcification in the stomach (gastric mucosa
and muscular layer), which was prominent in the ade-
nine-control group (Table 1).
PTH and ROD
Compared with the normal-control group, in the ade-
nine-induced renal failure rats, the serum PTH levels
were significantly elevated. It appeared that sevelamer
significantly suppressed serum PTH levels in adenine-
induced renal failure rats with secondary hyperparathy-
roidism throughout its administration (Fig. 9).
In the adenine-induced renal failure rats, histopathol-
ogy and morphometric analysis were used to determine
if sevelamer would suppress the ROD that had been
induced by elevated levels of serum PTH.
In this study, it was shown that sevelamer prevented
ROD as shown by a decrease in the presence of osteitis
fibrosa, porosity in the cortical bone, and osteoid histo-
pathologically in the femurs compared with the adenine-
induced renal failure rats (Fig. 10).
When a bone morphometric analysis was performed,
the adenine-induced renal failure rats showed changes
with regard to ROD, including a significant increase in
fibrosis volume, porosity ratio, and osteoid volume (Fig.
11). In the sevelamer-treated groups, all the changes
accompanying ROD were significantly improved com-
pared to the adenine-control group.
DISCUSSION
Clinically, Renagel has been reported to contribute
to lower serum phosphorus levels in hemodialysis pa-
tients [8–10]; and with electron beam tomography (EBT),
Renagel showed suppression of ectopic calcification in
the cardiovascular system [12]. In this study, we exam-
ined the effectiveness of sevelamer in preventing ectopic
calcification of soft tissues histopathologically and bio-
chemically in adenine-induced renal failure rats. Further-
more, a morphometric analysis was used to examine the
success of sevelamer in preventing ROD induced by
hyperparathyroidism. This study demonstrates that seve-
lamer, a calcium- and metal-free polymeric phosphate
binder, contributes to the prevention of ectopic calcifica-
tion of soft tissues and ROD by regulating the serum
phosphorus levels in adenine-induced renal failure rats.
A final benefit for regulation of the serum phosphorus
levels by Renagel could be the prevention of the ectopic
calcification and ROD in hemodialysis patients.
Adenine-induced renal failure rats have been shown
to exhibit hyperphosphatemia according to the severity
of chronic renal failure [15, 16]. Administration of an ade-
nine diet in rats resulted in the deposition of 2,8-dihy-
droxyadenine in the renal tubules, which consequently
induced a severe chronic renal failure due to the degener-
ation of the proximal and distal tubules and interstitial
fibrosis [13, 14]. This study demonstrated that, in ade-
nine-induced renal failure rats, elevated levels of serum
calcium  phosphorus product could induce an increase
in the ectopic calcification of soft tissues, including blood
vessels, kidney, and the muscular layer of the stomach.
Furthermore, ROD, which was induced by hyperpara-
thyroidism, was observed to have the characteristics of
osteitis fibrosa, with bone resorption cavities and in-
creased osteoid.
In this study, the adenine-induced renal failure rats
that were fed sevelamer did not develop significant epi-
sodes of ectopic calcification of the soft tissues, including
those tissues in the thoracic aorta, kidney, and stomach.
Hyperphosphatemia is accompanied by elevated levels
of serum calcium phosphorus product, and most stud-
ies on myocardial, vascular, and coronary artery calcifi-
cation among ESRD patients have reported a strong
association between calcification and serum phosphorus
and/or calcium  phosphorus product levels [18, 19].
Mo¨nckeberg’s medial sclerosis is one example of typical
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Fig. 10. Sevelamer prevents the progression of ROD in adenine-induced renal failure rats. (A to D ) show typical hematoxylin-eosin stains of
femur of normal controls (A), adenine controls (B and C), or 2% sevelamer-treated rats (D) at day 35 after administration. Increases in osteoid
(*), porosity in the cortical bone, fibrosa (Fb), the activation of osteoblasts (arrow) and osteoclasts (arrow head) were observed in adenine-induced
renal failure rats (C). Sevelamer prevented these pathologic findings of renal osteodystrophy (ROD). Magnification of (A, B, D), 2; magnification
of (C), 10.
vascular calcification in ERSD patients, which may have
two different pathogenic mechanisms: a degenerative
process that leads to apoptosis or necrosis of medial
smooth muscle cells, or an osteogenic process that leads
to formation of bone-like structures [20]. In hyperphos-
phatemia, it has recently been reported that phosphate
uptake on smooth muscle cells via a sodium-dependent
phosphate cotransporter, increases the expression of
Cbfa-1, a bone-specific transcription factor, and that sub-
sequent elaboration of a promineralizing matrix con-
taining osteopontin and osteocalcin can contribute to
vascular calcification [21]. In adenine-induced renal fail-
ure rats, the calcification of the aorta media, composed
of smooth muscle cells, is prominent and the vascular
calcification of this model has some histopathologic simi-
larity to Mo¨nckeberg’s medial sclerosis in uremic arterial
disease. It is assumed that the efficacies of sevelamer in
this study are in agreement with those of the vascular
calcification study in ESRD patients [12]. In the ESRD
patient study, sevelamer was associated with less pro-
gression of both coronary artery and aortic calcification
compared with calcium salts. In ESRD patients, arterial
calcification is strongly associated with arterial stiffening
and increased risk for cardiovascular and total mortality
[22, 23]. Coronary calcification in the ESRD population
is also associated with a history of cardiovascular events
[24]. Furthermore, we found that the aortas of adenine-
induced renal failure rats were positive for osteopontin
and osteocalcin, while the aortas not expressing ectopic
calcification by sevelamer administered were negative
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Fig. 11. Effect of sevelamer on morphomet-
rical parameters of ROD. Fibrosis volume
(A ), porosity ratio (B ), and osteoid volume
(C ) were significantly elevated in adenine-
induced renal failure rats. However, sevelamer
significantly suppressed these morphometric
parameters representing the features of renal
osteodystrophy (ROD). Data are mean SE.
#P  0.05 vs. normal-control group; **P 
0.01; ***P  0.001 vs. adenine-control group.
for these expressions. These data suggested that hyper-
phosphatemia induced the osteoblastic differentiations
(although the metastatic bone formation was not observed)
in the vascular calcification of adenine-induced renal fail-
ure rats, while sevelamer suppressed these changes.
As for nephrocalcinosis, calcification of the kidney was
observed in tubular epithelial cells and their basement
membrane in adenine-induced renal failure rats. The
adenine-induced renal failure rats showed an elevated
level of serum PTH, possibly due to increased serum
phosphorus levels. Along with elevated levels of serum
calcium  phosphorus product, the elevated levels of
serum PTH also can induce retention of calcium in the
renal tubular cells, which may cause the nephrocalcinosis
of tubules and the worsening of renal function [25, 26].
Therefore, it is assumed that the effectiveness of seve-
lamer, in the prevention of nephrocalcinosis, has two
mechanisms—one is a direct suppression of serum cal-
cium  phosphorus product levels, and the other is an
indirect effect by decreasing serum PTH levels. As for
the serum creatinine, the values showed no significant
differences among all groups in our experiment, although
data from Cozzolino et al [11] showed improvement of
renal function by reduced nephrocalcinosis. The reason
is because the adenine-induced renal failure models in
this experiment condition were extremely severe (serum
creatinine was extremely high), and the suppression of
nephrocalcinosis was not enough to prevent the progres-
sion of renal failure.
This study also demonstrated that the sevelamer-
treated groups showed a significant suppression of serum
PTH levels, while the adenine-induced renal failure con-
trol rats, with secondary hyperparathyroidism, showed
a greatly increased elevation of serum PTH levels. Sec-
ondary hyperparathyroidism is known to be induced by
low levels of serum calcium and 1,25(OH)2D3 in chronic
renal failure patients [27, 28]. Besides this pathway, it
has been recently demonstrated that serum phosphorus
levels increase the synthesis and secretion of PTH in
vitro, and in experimental animals; phosphorus also plays
an important role in the development of parathyroid cell
hyperplasia [29–31]. In this study, extremely elevated
levels of serum phosphorus and decreased levels of se-
rum calcium were thought to cause an elevation in the
levels of serum PTH, along with increased hyperplasia
of the parathyroid glands.
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The results of this study indicate that sevelamer sig-
nificantly prevents ROD that is induced by hyperpara-
thyroidism in adenine-induced renal failure rats. Second-
ary hyperparathyroidism is known to induce a high
turnover bone disease (ROD), characterized by in-
creases in the activation of osteoblasts and osteoclasts
with elevated rates of bone formation [6–8], which is
responsible for a significant rate of morbidity. In this
experiment, adenine-induced renal failure rats show a
marked high turnover type of ROD via elevated levels
of serum PTH, which histopathologically represents the
activation of osteoblasts and osteoclasts, osteitis fibrosa,
an increase in bone resorption cavities, a dramatic in-
crease in the production of osteoids in the endosteum,
and a decrease in bone marrow cavity. The histopathol-
ogy of this model is similar to the mixed type of ROD
in ESRD patients, which is characterized by an increase
in osteitis fibrosa and osteoid. Sevelamer contributes to
the prevention of a progression of ROD in adenine-
induced renal failure rats, as well as preventing an in-
crease in osteoid, bone resorption cavities, and osteitis
fibrosa. Our data indicate that sevelamer could be a
useful compound in treating ROD that is caused by sec-
ondary hyperparathyroidism.
CONCLUSION
The adenine-induced renal failure rat may provide a
model to test therapeutic agents to prevent both ROD
and ectopic calcification. The results indicated that seve-
lamer was effective in suppressing ectopic calcification
and ROD in adenine-induced renal failure rats.
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